OFFICE OF THE SECRETARY OF STATE
TOBIAS READ
SECRETARY OF STATE

MICHAEL KAPLAN
DEPUTY SECRETARY OF STATE

ARCHIVES DIVISION
STEPHANIE CLARK
DIRECTOR

800 SUMMER STREET NE
SALEM, OR 97310
503-373-0701

TEMPORARY ADMINISTRATIVE ORDER

INCLUDING STATEMENT OF NEED & JUSTIFICATION

BP 4-2026

CHAPTER 855

BOARD OF PHARMACY

FILED

02/25/2026 2:21 PM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

FILING CAPTION: Medications for Opioid Use Disorder Protocols; Continuation of Therapy

EFFECTIVE DATE: 02/25/2026 THROUGH 08/23/2026

AGENCY APPROVED DATE: 02/12/2026

CONTACT: Rachel Melvin
971-673-0001
pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150
Portland,OR 97232

Filed By:
Rachel Melvin
Rules Coordinator

NEED FOR THE RULE(S):

Temporarily amends rule by adopting a revised version of Continuation of Therapy protocol and adds new protocols for Medications for Opioid Use Disorder for Initiation of Care and Continuation/Modification of Care.

JUSTIFICATION OF TEMPORARY FILING:

Failure to adopt new Medications for Opioid Use Disorder protocols and revised Continuation of Therapy protocol may result in compromised patient access and care by leaving individuals vulnerable and potentially overwhelming other healthcare providers.

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE:

ORS 689.698 https://www.oregonlegislature.gov/bills_laws/ors/ors689.html
February 2026 Bd Mtg
Mailing #Aa Continuation of Therapy protocol, Mailing #Ab – Medications for Opioid Use Disorder – Initiation of Care protocol, Mailing #Ac – Medications for Opioid Use Disorder – Continuation/Modification of Care protocol
https://www.oregon.gov/pharmacy/Documents/February_2026_Bd_Mtg_Agenda.pdf

AMEND: 855-115-0345

RULE TITLE: Services: Prescribing Pursuant to - Protocol

RULE SUMMARY: Amends the lead in by adding “pharmacists can prescribe pursuant to the protocols listed below” to provide clarity. Amends (1) by revising the Continuation of Therapy protocol by removing language related to early refills of non-controlled opioid use disorder medications as mandated by revised statutory language. Adopts two new protocols in (3)(j)(k) for Medications for Opioid Use Disorder (MOUD) for Initiation of Care and Continuation/Modification of Care as mandated by 2025 SB 236 (ORS 689.698).

RULE TEXT:
A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, FDA-approved drugs and devices pursuant to a Protocol. Protocols in their entirety are adopted by the board by this rule pursuant to the respective effective date referenced and can be found on the board website at

https://www.oregon.gov/pharmacy/Pages/PFAC.aspx. Pharmacists can prescribe pursuant to the protocols listed below.

(1) Continuation of Therapy Protocol including emergency refills of insulin (v. 02/2026).

(2) Conditions Protocols:

(a) Cough and cold symptom management:

(A) Benzonatate (v. 06/2021);

(B) Short-acting beta agonists (v. 06/2021);

(C) Intranasal corticosteroids (v. 06/2021);

(b) COVID-19 Antigen Self-Test (v. 12/2021);

(c) SARS-CoV-2 Antiviral (v. 08/2024).

(3) Preventative Care Protocols:

(a) Emergency Contraception (v. 06/2021);

(b) Male and female condoms (v. 06/2021);

(c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT (v. 06/2024);

(d) Travel Medications (v. 06/2024);

(e) HIV Post-exposure Prophylaxis (PEP) (v. 01/2026);

(f) HIV Pre-exposure Prophylaxis (PrEP) (v. 01/2026);

(g) Contraception (v. 06/2025);

(h) Sexually Transmitted Infections Post-exposure Prophylaxis (STI PEP) (v. 06/2024);

(i) Short-acting Opioid Antagonists (v. 06/2024);

(j) Medications for Opioid Use Disorder - Initiation of Care (v. 02/2026); and

(k) Medications for Opioid Use Disorder - Continuation/Modification of Care (v. 02/2026).

(4) Vaccine Protocols:

(a) Vaccination Protocol for Adults 18 Years of Age and Older (v. 01/2026);

(b) Vaccination Protocol for Ages 7 through 17 Years (v. 01/2026); and

(c) Vaccination Protocol for Managing Adverse Reactions (v. 08/2025).

(5) Board Excluded Vaccine Protocols:

(a) Coronavirus 19 (v. 01/2026);

(b) Influenza (v. 01/2026); and

(c) Respiratory Syncytial Virus (v. 09/2025).

[Publications: Publications referenced are available from the agency.]

STATUTORY/OTHER AUTHORITY: ORS 689.205, ORS 689.005, ORS 689.698

STATUTES/OTHER IMPLEMENTED: ORS 689.645, ORS 689.649, ORS 689.689, ORS 689.005, ORS 689.698